Sensorion
Sensorion [ALSEN] is a biopharmaceutical company, formed in 2009, focused as a “pure player” on developing therapies for debilitating inner ear disorders. Sensorion’s mission is to offer innovative therapeutic solutions providing long-term improvements to people living with, or at risk of, inner ear disorders. Sensorion’s portfolio of solutions to unmet medical and social needs in inner ear disorders rests on three pillars – Restore, Treat, Prevent.
Sector
Biopharmaceuticals
Strategies
Crossover
Status
Live
Website
www.sensorion.com
Related News
Sensorion announces positive recommendation from the Data Safety Monitoring Board (DSMB) regarding the continuation of NOTOXIS, its Phase 2a clinical trial of SENS-401 in cisplatin-induced ototoxicity
Sensorion announces new positive secondary efficacy endpoints data from SENS-401 Phase 2a clinical trial for the preservation of residual hearing loss
Sensorion announces the appointment of Laurene Danon as Chief Financial Officer
Sensorion announces a €15 Million financing, extending cash runway until the end of 2025
Sensorion announces it has met primary endpoint for SENS-401 Phase 2a Clinical Study for residual hearing preservation
SofinnovaCapital
The Sofinnova Capital Strategy is our flagship fund, investing as founding or lead investor in early-stage biopharma and medtech start-ups developing groundbreaking therapeutic technologies.
SofinnovaMD Start
The Sofinnova MD Start Strategy is our in-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy invests in growth-stage biotech and medtech companies that have clinically validated their technologies and are preparing for commercialization.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy invests in early-stage sustainable companies across the agriculture, chemicals, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy makes early-stage investments in leading Italian science for the benefit of patients around the world.
SofinnovaDigital Medicine
Our Digital Medicine Strategy backs early-stage techbio and healthtech start-ups at the intersection of biology, data, and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is our biotech accelerator, partnering with leading research organizations to create and build European biotech start-ups.